特集 神経疾患治療の進歩 2017
末梢神経疾患の治療の進歩
キーワード:
diabetic neuropathy,
chemotherapy–induced neuropathy,
POEMS syndrome,
chronic inflammatory demyelinating polyneuropathy
2018 年 35 巻 5 号 p. 617-619
詳細
2018 年 35 巻 5 号 p. 617-619
Various clinical trials for peripheral neuropathy were published in 2017. Systematic PubMed search using terms, “neuropathy”, “peripheral neuropathy”, “treatment”, “therapy”, and “clinical trials” was performed with the time lock from January 1, 2017 through December 31, 2017. Twenty–four clinical trials were detected on diabetic neuropathy (DPN), chemotherapy–induced peripheral neuropathy (CIPN), hereditary ATTR amyloidosis, POEMS syndrome, Guillain–Barre syndrome (GBS), and chronic inflammatory demyelinating polyneuropathy (CIDP). For painful DPN, pregabalin, capsaicin patch, and spinal cord electric stimulation were effective for pain relief. For CIPN, capsaicin patch and glutamine treatment showed possible beneficial effects. For ATTR amyloidosis, post–hoc analysis of the pivotal tafimidis trial revealed that the drug significantly delayed neuropathy progression, whereas a protocol paper for siRNA therapy was published. For POEMS syndrome, GBS, and CIDP, a novel treatment for each disorder finished or is on–going. These results showed sustained research activity to develop new therapies for a number of peripheral nerve disorders.
